Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027...
April 27, 2026 16:30 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting

- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a...
April 07, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
March 23, 2026 09:25 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors

SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for...
March 12, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal...
February 23, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor...
November 06, 2025 09:00 ET | Source: Precedence Research

CAR T-Cell Neurotoxicity Detection Market Overview and Strategic Developments by Towards Healthcare

Ottawa, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The CAR T-cell neurotoxicity detection market is rapidly emerging as a crucial segment in oncology diagnostics, propelled by the growing adoption of CAR...
October 06, 2025 11:07 ET | Source: Spherix Global Insights

US Rheumatologists View Cell Therapy as a Potential Game Changer, with Systemic Sclerosis Emerging as the Most Compelling Indication, According to Spherix Global Insights

EXTON, PA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists reporting highly favorable...
September 30, 2025 07:55 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Announces that UB-VV111 Receives FDA Fast Track Designation for Relapsed/Refractory B-Cell Malignancies

SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced today that...
September 23, 2025 07:55 ET | Source: Umoja Biopharma, Inc.

Umoja Biopharma Named One of 2025’s Most Promising Biotech Companies by Endpoints News and Fierce Biotech

SEATTLE, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced its...